EarningsHTGC offers a durable NOI profile with its earnings multiple now more in line with upper quartile peers.
Market ExpansionLivmarli's approval in Japan positions it for double-digit royalties on net sales, which is seen as a positive financial upside.
Product ApprovalLivmarli becomes the first approved drug for cholestatic pruritus in patients with ALGS and PFIC, marking a significant step in its global expansion.